Trial · NCT06028438
Adverse events30
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 30
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Bronchitis | Infections and infestations | Group 1: Certolizumab and Placebo | 0 | 41 | |
| other | Bronchitis | Infections and infestations | Group 2: Certolizumab and Nipocalimab | 4 | 62 | |
| other | Nasopharyngitis | Infections and infestations | Group 1: Certolizumab and Placebo | 2 | 41 | |
| other | Nasopharyngitis | Infections and infestations | Group 2: Certolizumab and Nipocalimab | 5 | 62 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Group 1: Certolizumab and Placebo | 1 | 41 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Group 2: Certolizumab and Nipocalimab | 4 | 62 | |
| other | Urinary Tract Infection | Infections and infestations | Group 1: Certolizumab and Placebo | 1 | 41 | |
| other | Urinary Tract Infection | Infections and infestations | Group 2: Certolizumab and Nipocalimab | 4 | 62 | |
| other | Rheumatoid Arthritis | Musculoskeletal and connective tissue disorders | Group 1: Certolizumab and Placebo | 0 | 41 | |
| other | Rheumatoid Arthritis | Musculoskeletal and connective tissue disorders | Group 2: Certolizumab and Nipocalimab | 4 | 62 | |
| other | Headache | Nervous system disorders | Group 1: Certolizumab and Placebo | 3 | 41 | |
| other | Headache | Nervous system disorders | Group 2: Certolizumab and Nipocalimab | 4 | 62 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Group 1: Certolizumab and Placebo | 1 | 41 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Group 2: Certolizumab and Nipocalimab | 4 | 62 | |
| serious | Myocardial Infarction | Cardiac disorders | Group 1: Certolizumab and Placebo | 0 | 41 | |
| serious | Myocardial Infarction | Cardiac disorders | Group 2: Certolizumab and Nipocalimab | 2 | 62 | |
| serious | Cellulitis | Infections and infestations | Group 1: Certolizumab and Placebo | 0 | 41 | |
| serious | Cellulitis | Infections and infestations | Group 2: Certolizumab and Nipocalimab | 1 | 62 | |
| serious | Influenza | Infections and infestations | Group 1: Certolizumab and Placebo | 0 | 41 | |
| serious | Influenza | Infections and infestations | Group 2: Certolizumab and Nipocalimab | 1 | 62 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06028438/events